Daniel Duberg

Daniel Duberg

Auto-generated profile, based on publicly available information

Daniel Duberg

School of Science and Technology, Örebro University, SE-702 81 Örebro, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SGShashank Gupta
Shashank Gupta
OJOveis Jamialahmadi
Oveis Jamialahmadi
RMRosellina Margherita Mancina
Rosellina Margherita Mancina
DDDaniel Duberg
Daniel Duberg
Umberto Vespasiani-GentilucciUmberto Vespasiani-Gentilucci
Umberto Vespasiani-Gentilucci
Matej OresicMatej Oresic
Matej Oresic
Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits marked heterogeneity and sex differences, yet the molecular mechanisms underlying disease progression remain incompletely understood. Here, we present the largest integrative multi-omics study to date combining matched liver tissue and blood profiling in 211 biopsy-confirmed, morbidly obese individuals with MASLD undergoing bariatric surgery. We integrate hepatic transcriptomics, metabolomics, and lipidomics with serum metabolomics to resolve compartment-specific and sex-dependent molecular networks. Across sexes, MASLD is characterized by suppressed hepatic amino acid metabolism and extensive lipid remodeling, accompanied by inverse metabolic signatures in circulation, consistent with systemic spillover. Strikingly, disease progression in men is driven by a streamlined triacylglycerol-centric pathway that mediates transcriptional effects on steatosis and inflammation, whereas women exhibit distributed, multi-layered networks linking lipid, amino acid, and immune pathways. Mediation analyses identify hepatic lipid modules as key intermediates connecting gene expression to histopathology. These findings reveal sex-specific molecular architectures of MASLD, demonstrate that circulating biomarkers do not reflect hepatic metabolism, and provide a framework for sex-specific precision medicine.

26 October 2025 in bioRxiv
Verified
Preprint
Open access
AAAndi Alijagic
Andi Alijagic
Jade ChakerJade Chaker
Jade Chaker
JBJoão Marcos G. Barbosa
João Marcos G. Barbosa
DDDaniel Duberg
Daniel Duberg
VCVictor Castro-Alves'
Victor Castro-Alves'
Tuulia HyötyläinenTuulia Hyötyläinen
Tuulia Hyötyläinen
Perfluorohexyloctane (F6H8) is a semifluorinated alkane recently approved for ophthalmic treatment of dry eye disease. Although considered locally safe for topical use, its structural similarity to persistent per- and polyfluoroalkyl substances (PFAS) raises concerns about systemic accumulation and long-term toxicity. To investigate potential hepatic effects, we examined the metabolic impact of F6H8 exposure in human HepaRG hepatocytes across a broad concentration range representing short- and long-term exposure scenarios. Untargeted metabolic profiling by ultra-high-performance liquid chromatography–quadrupole time-of-flight mass spectrometry (UHPLC-ǪTOFMS) was performed on intracellular extracts and extracellular media. F6H8 induced pronounced, concentration-dependent metabolic alterations, many of which exhibited non-monotonic responses. Low concentrations primarily affected amino acid, fatty acid, and lipid metabolism, while central carbon metabolism was disrupted only at the highest exposures. Notably, a putative biotransformation product, perfluorohexyloctanoic acid, was detected, suggesting metabolic persistence and conversion to a PFAS-like structure. These findings indicate that F6H8 elicits broad metabolic reprogramming and may not be metabolically inert as previously assumed. Given its clinical use and structural similarity to persistent fluorochemicals, the results highlight the need for comprehensive, long-term safety assessment of F6H8 and related semifluorinated alkanes.

8 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
HRHenrique C. Ribeiro
Henrique C. Ribeiro
Alex DickensAlex Dickens
Alex Dickens
DDDaniel Duberg
Daniel Duberg
Jussi PostiJussi Posti
Jussi Posti
AMAndrew I. R. Maas
Andrew I. R. Maas
INInvestigators
Investigators
Patients presenting with a Glasgow Coma Scale (GCS) score of 13–15, conventionally labelled mild traumatic brain injury (mTBI), account for most hospital-presenting TBI; a substantial proportion have not recovered to pre-injury health at six months, fewer than one in ten receives structured follow-up, and at presentation they are largely indistinguishable from those who recover. Prognostic models based on clinical variables discriminate poorly here, and established protein biomarkers add little. Lipidomics reflects membrane turnover and repair rather than injury magnitude, offering a potentially complementary perspective. Blood collected within 24 h of injury from 929 patients with mTBI in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) cohort was processed to serum and analysed by Ultra-high performance liquid chromatography – Quadrupole-Time-of-flight mass spectrometry (UHPLC-QTOF). After quality-control, 278 lipid features were retained and clustered by Gaussian mixture modelling. Associations between lipid features, six protein biomarkers, Corticosteroid Randomisation After Significant Head injury (CRASH) clinical variables and 6-month Glasgow Outcome Scale–Extended (GOSE) outcome were assessed by Spearman correlation and Jonckheere–Terpstra trend tests. Variables were selected by ordinal elastic-net and modelled by proportional odds logistic regression, comparing CRASH-only with CRASH-plus-marker models, built in a development set (n = 411 with complete covariates) and assessed in a test set (n = 367). Lipid clusters rich in lysophosphatidylcholines (LPCs), sphingomyelins/ceramides and ether-linked phosphatidylcholines (PC-O) correlated positively with favourable outcome and inversely with the injury proteins. Summed choline-containing lipid intensity rose across GOSE (p < 0.0001). Elastic-net selected three proteins (GFAP, NfL, S100B) and seven lipid features, three annotated (LPC(18:2), LPC(20:5), PC(O-34:3)). Adding lipids and proteins increased the area under the receiver operating characteristic curve (AUC) at every threshold, reaching nominal significance at GOSE ≥ 7 (AUC 0.728, 95% CI 0.671–0.785, p = 0.022), not surviving correction for four comparisons. The averaged c-index rose from 0.720 to 0.751 and Nagelkerke R 2 from 0.125 to 0.242. The three proteins and three annotated lipids showed opposing trends across GOSE (all p < 0.001). The acute serum lipidome is associated with 6-month functional outcome after mTBI. LPCs and PC-Os moved opposite to the injury proteins and may index membrane repair rather than injury burden, offering pathophysiological insight and possible therapeutic targets. Adding them to clinical variables gave modest gains, greatest at the upper end of the outcome scale, where existing models perform worse. The gain is small and exploratory; replication with targeted assays is needed first.